[Corrigendum] DR2 blocker thioridazine: A promising drug for ovarian cancer therapy
- Authors:
- Published online on: September 9, 2020 https://doi.org/10.3892/ol.2020.12081
- Article Number: 218
-
Copyright : © Yong et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article
Oncol Lett 14: [Related article:] 8171-8177, 2017; DOI: 10.3892/ol.2017.7184
Subsequently to the publication of the above article, and a Corrigendum that has already been published to show corrected versions of Figs. 1 and 2 (DOI: /10.3892/ol.2020.11285; published online on January 9, 2020), the authors have realized that Fig. 4D also featured the incorrect placement of a data panel; essentially, the data panel shown for the A2780, thioridazine experiment was a duplicate of the SKOV3, thioridazine data panel.
The corrected version of Fig. 4, featuring the correct data for the A2780, thioridazine experiment, is shown on the next page. All the authors agree to this Corrigendum. Note that the revisions made to these figures do not adversely affect the results reported in the paper, or the conclusions stated therein. The authors regret that this additional error was not noticed prior to the publication of this article, and offer their apologies to the Editor and to the readers of the Journal.